When working with CAR T-cell therapy, a personalized immunotherapy that engineers a patient’s own T cells to recognize and destroy cancer cells. Also known as CAR‑T, it has reshaped treatment for certain blood cancers. This approach blends immunotherapy, the use of the body’s immune system to fight disease with cutting‑edge gene editing, precise DNA modifications that insert a chimeric antigen receptor into T cells. The resulting chimeric antigen receptor, a synthetic protein that gives T cells a new target‑finding capability directs the modified cells toward cancer‑specific markers, such as CD19 on B‑cell malignancies. In practice, doctors collect a patient’s blood, isolate T cells, use a viral vector or CRISPR system to add the CAR gene, expand the cells in a lab, and infuse them back. The therapy therefore requires a sophisticated manufacturing pipeline, rigorous quality checks, and close clinical monitoring. In short, CAR T-cell therapy combines gene editing, immunotherapy, and targeted oncology into a single treatment modality.
